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Objectives: Artemisinin combination based therapy (ACT) was started in Ghana in 
2002 as a result of failure of monotherapy in the treatment of falciparum malaria. 
The decision to change was in line with recommendations from the World Health 
Organisation. ArtesunateAmodiaquine (A-Q) is the preferred combination drug of 
choice for the treatment of uncomplicated malaria and Artemether-Lumefantrine 
(A-L) is an alternative first line option. This study evaluates the cost-effectiveness 
of A-Q compared with A-L among under-five year olds in Ghana. MethOds: In 
this study a decision analytic model using a decision tree was developed to assess 
the cost-effectiveness of the two treatments. Cost of illness and cost of medication 
(Coartem paediatric and Camoquine plus) were determined using figures from the 
National Health Insurance Scheme (NHIS) Ghana and from wholesalers respectively. 
Transportation cost was estimated using exit interviews. With the help of rand-
omized controlled trials we estimated malaria cases averted (using clinical failure 
rates) over a 28 day period post treatment with each drug. Costs were discounted 
by 3% over a five year period but malaria cases averted 28 days after treatment 
was not discounted. Incremental costs per uncomplicated malaria case averted 
was then determined. Results: The cost of illness per episode of uncomplicated 
malaria was 7.50 Ghana cedis (bundled NHIS cost) and transportation cost was 3.00 
Ghana cedis. The incremental cost effectiveness ratio of artesunate-amodiaquine 
compared with artemether-lumefantrine was 16 Ghana cedis per uncomplicated 
malaria case averted. cOnclusiOns: This economic evaluation showed that in the 
Ghanaian setting, treating uncomplicated malaria in under-five year old children 
with artesunate-amodiaquine was more cost-effective compared with artemether-
lumefantrine.
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Objectives: Favorable clinical outcomes in HIV-1 infection require optimal 
adherence to multi-drug antiretroviral (ARV) regimens. Single-tablet regimens 
(STRs) simplify treatment compared with multiple-tablet regimens (MTRs) and are 
associated with improved adherence, improved virologic outcomes and reduced 
hospitalizations. To date, models assessing the economic value of STRs have been 
based only on clinical trial evidence from idealized settings with close follow-up. 
Economic models have not yet incorporated real-world evidence comparing adher-
ence and effectiveness between STRs and MTRs. MethOds: A patient-level simu-
lation model was used to compare health and economic outcomes between STRs 
and MTRs in the US. STRs included EVG/COBI/FTC/TDF, EFV/FTC/TDF and RPV/FTC/
TDF. MTRs included a 3rd agent plus 3TC+TDF backbone. Before incorporating real-
world evidence, the model was validated against published economic projections 
based on clinical trial results. Real-world evidence identified via systematic litera-
ture review was then incorporated for differences in adherence, resistance, and 
hospitalization risk between STRs and MTRs. Upcoming generic drug scenarios 
included 25-75% cost reductions and lower average drug costs for MTRs vs. STRs 
by $1,300 to $6,100 per year. All costs were inflated to 2013 USD. Results: After 
incorporating real-world evidence, the virologic suppression rates at 24 weeks 
were 72.7% and 63.2% for STRs and MTRs, respectively. When initiating with STRs 
vs. MTRs, short-term inpatient costs (at 2 years) were reduced by 29% ($7,660 vs. 
$10,819) and an additional 2 life years (20.6 vs. 18.6) were gained. The discounted 
life-time incremental cost-effectiveness ratios ranged from ~$26,000 to $52,000 
per QALY, depending on assumed generic discounts. cOnclusiOns: STRs have 
demonstrated superior clinical and economic outcomes compared to MTRs in 
real-world settings. Incorporating this evidence into a cost-effectiveness model 
illustrated that initiation with STRs is a cost-effective strategy compared with 
initiation with MTRs, due to greater real-world adherence and effectiveness, and 
reduced inpatient costs.
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Objectives: In the United States, chronic hepatitis C (HCV) is responsible for more 
death and disease than HIV/AIDS. It is the most common chronic blood-borne infec-
tion, and remains a major cause of death and illness in the United States. Current 
standard of care treatments for HCV have difficult dosing regimens and are often 
accompanied by undesirable side effects. With a host of new clinically promis-
ing, interferon-free, combo therapies currently in clinical trials it is important to 
assess the cost-effectiveness of the current and future treatment options for chronic 
hepatitis C. The objective of the current study is to assess the cost-effectiveness 
of current, and future, treatment options for treatment naïve genotype 1 chronic 
hepatitis c patients. MethOds: Cost-effectiveness analysis using a Markov model 
of the natural disease progression of HCV infection and impact of treatment. We 
use a simulated 20 year model of a hypothetical cohort of 1000 treatment naïve 
genotype 1 HCV patients to assess the cost-effectiveness of no treatment, boceprevir 
+ pegylated interferon + ribavirin (BOC+P+R), telaprevir + pegylated interferon + 
ribavirin (TVR+P+R), and sofosbuvir + ledipasvir + ribavirin (SOF+LVR+R). Results: 
Over the 20 year time horizon of this cohort no treatment would result in 9.76 QALYs 
and a total discounted cost of $41,434, while BOC+P+R resulted in 11.06 and $132,070, 
TVR+P+R in 11.08 and $132,482, and SOF+LVR+R in 11.90 and $172,384, respectively. 
Our analysis showed that BOC+P+R and TVR+P+R were weakly dominated, while 
SOF+LVR+R was the most cost-effective therapy. cOnclusiOns: The interferon-free 
combo therapy SOF+LVR+R is the most cost-effective treatment option, with an ICER 
of $61,291 when compared to no treatment. These results have important economic, 
and policy implications for the treatment of chronic hepatitis C.
Objectives: The purpose of this cost-effectiveness model is to compare the cost-
effectiveness of metronidazole, oral vancomycin, fidaxomicin, and fecal transplants 
for CDI. MethOds: This is a cost-effectiveness model from the societal perspective 
using probabilities, cost, and utility parameters from scientific literature. A deci-
sion tree model for mild/moderate CDI compares metronidazole, oral vancomycin, 
fidaxomicin, and fecal transplant. A decision tree for severe CDI compares oral 
vancomycin, fidaxomicin, and fecal transplant. Both decision trees capture up to two 
recurrences and/or the necessity of a colectomy. Both models account for short-term 
and long-term costs of CDI. One-way sensitivity and threshold sensitivity analy-
sis were used to assess the robustness of the data. Results: For mild-moderate 
CDI, fecal transplant is a dominant treatment option, as it reduces costs to $13,537 
and increases effect to 11.85 QALYs. The best alternative to fecal transplants in 
mild-moderate disease is fidaxomicin if WTP/QALY > $0. For severe disease, fecal 
transplant is still a dominant treatment option, as it reduces costs to $13,537 and 
increases effect to 11.84 QALYs. The best alternative to fecal transplants in severe 
CDI is oral vancomycin at all WTP/QALY. For mild-moderate disease indicated that 
fecal transplants are favored to fidaxomicin as long as the cost of fecal transplants 
< $4,515, fecal transplant cure rate > 0.883, fecal transplant recurrence rate < 0.185, 
fidaxomicin cure rate < 0.955, and fidaxomicin recurrence rate > 0.02. For severe 
disease indicated that fecal transplants are favored to oral vancomycin as long as 
the cost of fecal transplants < $4,860, fecal transplant cure rate > 0.79, and the fecal 
transplant recurrence rate < 0.36. cOnclusiOns: In both the treatment of mild/
moderate and severe CDI, it is cost-effective to use fecal transplants as standard 
protocol rather than the last resort.
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Objectives: To compare Ertapenem with ceftriaxone for the treatment of uri-
nary tract infections (UTI) in Colombia health care setting, with respect to cost 
and outcomes taking into account development of anti-microbial resistance 
(AMR). MethOds: A previously published decision tree model was adapted to 
estimate cost-effectiveness of Ertapenem vs. Ceftriaxone in the treatment of UTI. 
Clinical efficacy, adverse events and medical resource use were derived from lit-
erature. AMR to Ertapenem and ceftriaxone was calculated as weighted average 
based on the % distribution of different pathogens in UTI in Colombia and the 
sensitivity of Ertapenem and Ceftriaxone to each pathogen from Colombia SMART 
data. The resistance-adjusted effectiveness is then computed based on the effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall AMR of Ertapenem vs. Ceftriaxone for UTI is 7% 
vs. 30%. The resistance-adjusted effectiveness is 83% vs. 64% for Ertapenem vs. 
Ceftriaxone. Daily drug costs for Ertapenem vs. Ceftriaxone are 133,550 vs. 8,550 
Colombian Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line 
treatment & cost of AEs) are 446,871 vs. 188,268 Pesos. During the first hospitaliza-
tion period, Ertapenem is associated with a 18.8% higher treatment success rate, 
and 178,377 Pesos more in total cost when compared with Ceftriaxone. The incre-
mental cost per successfully treated patient (ICER) is 9,488 Pesos ($4.87 USD) for 
Ertapenem vs. Ceftriaxone. cOnclusiOns: Accounting for local anti-microbial 
resistance, Ertapenem is more effective as well cost-effective vs. Ceftriaxone for 
the treatment of urinary tract infections in Colombia.
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Objectives: Dolutegravir is a new FDA-approved (August 2013) antiretroviral medi-
cation in the integrase inhibitor class which could be a possible first-line agent for 
treatment of antiretroviral naïve HIV infected adults. A phase III trial (SPRING-2) 
compared clinical efficacy of dolutegravir versus raltegravir, a currently recom-
mended first-line agent, and demonstrated non-inferior viral response rates at 96 
weeks for dolutegravir (81%) when compared to raltegravir (76%). This study aims to 
estimate the costs and effectiveness of dolutegravir and raltegravir and to determine 
the cost-effectiveness of dolutegravir versus raltegravir. MethOds: A decision anal-
ysis model was constructed to determine the cost-effectiveness of treatment with 
dolutegravir versus treatment with raltegravir as a first-line agent from the perspec-
tive of the provider. First-line efficacy data was derived from the previously-men-
tioned published phase-III trial (SPRING-2). Drug costs were estimated using average 
whole sale price and data were obtained using the Red Book. Costs associated with 
second-line treatment as well as adverse effect treatment were also derived from 
the Red Book. The model was run over a period of 192 weeks using TreeAge Pro 
2013. Results: The estimated costs for the dolutegravir arm and raltegravir arm 
at 192 weeks were $100,750.28 and $96,622.17, respectively. The incremental cost-
effectiveness ratio for dolutegravir versus raltegravir was estimated to be $412,811 
per 1% increase in virological success. Sensitivity analysis performed on the cost 
parameters confirmed the primary cost effectiveness results. cOnclusiOns: The 
analysis provided cost-effectiveness findings of dolutegravir versus raltegravir for 
HIV-infected treatment naïve patients and showed favorable cost-effectiveness 
results for raltegravir when using a 192 week time frame.
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tively. Thus, conclusions from ICER and MDA assessments are consistent. To inves-
tigate the model robustness, we performed one-way and probabilistic sensitivity 
analyses. All sensitivity analyses illustrated that MDA dominated EIA and CA within 
the predefined ranges of input variables. cOnclusiOns: Our study demonstrated 
that the routine use of MDA for CDI patients would result in substantial savings 
and improved health outcomes in US patients, compared to traditional diagnostic 
assays for this infection. These are the first data to evaluated QALY outcomes as 
they may vary with diagnostic test choice for CDI.
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Objectives: Determine the cost-effectiveness of becaplermin gel* on wound heal-
ing for the treatment of pressure ulcers (PU). MethOds: A 2-stage Markov model 
was used to predict expected costs and outcomes of wound healing for becaplermin 
gel once daily compared to placebo gel over a 1-year time period. Outcome data used 
in the analysis were derived from a 16-week randomized clinical trial. Primary out-
come of interest was ulcer-free weeks. A total of 61 patients completed the study; 31 
for becaplermin gel once-daily, and 30 for placebo gel. Patients in both arms received 
dressing changes twice daily. Patients in the treatment arm received becaplermin 
gel once daily followed by placebo gel. Transition probabilities for the Markov states 
were estimated from the clinical trial. Ulcer recurrence rates were derived from PU 
literature. Utilization for becaplermin gel was calculated using the manufacturer’s 
recommended dosing algorithm for diabetic foot ulcers. Costs were derived from 
standard cost references and medical supply wholesalers. The economic perspec-
tive taken was that of the payer. Results: Wound closure for patients treated with 
becaplermin gel was significantly (p< 0.01) higher compared to placebo gel (23% 
versus 0%, respectively) at 16 weeks. Over 1-year, patients treated with becaplermin 
gel had substantially higher ulcer-free weeks compared to placebo patients (13.5 
versus 0.0, respectively). Patients treated with becaplermin gel incurred higher total 
costs than those receiving placebo. Expected annual direct costs for PU were $3,234 
for becaplermin gel and $1,222 for placebo. The incremental cost-effectiveness ratio 
(ICER) was $149 (approximately $21/day), indicating that patients would have to pay 
an extra $149 to gain one additional ulcer-free week. cOnclusiOns: Becaplermin 
gel was cost-effective over placebo, yielding better outcomes at a slightly higher 
cost. In addition, becaplermin gel is an effective treatment for wound healing and 
should be considered for use in the management of pressure ulcers. *Regranex®, 
Smith & Nephew Biotherapeutics, Fort Worth, Texas
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Objectives: To determine the cost effectiveness of colistimethate sodium for 
the treatment of infections caused by multidrug-resistant (MDR). MethOds: We 
compare key outcomes related to survival, infection averted and costs for infec-
tions caused by MDR. A lifetime Markov model was used to estimate the expected 
outcomes and costs for patients treated with colistimethate sodium vs non- colis-
timethate sodium group. Colistimethate sodium at a dosage of 5mg/kg/day was 
given intravenously in two divided doses. Primary outcomes were the clinical 
response and 30-day mortality; secondary outcomes were microbiological response 
and adverse events. The cost-effective analysis was conducted from the Mexican 
Health care perspective. Costs were derived from the literature, future costs and 
effects were discounted at 5% per recommendations for analyses in Mexico. All 
costs are presented in 2013 US dollars. Multiple 1-way and Probabilistic sensitivity 
analyses were performed. Results: In the colistimethate sodium group, 80.8% 
had a favorable clinical response, the overall mortality of the patients in the colis-
timethate sodium group was 46.2% and that in the non- colistimethate sodium 
group was 80%. Nephrotoxicity was found in 30.8% in the colistimethate sodium 
group. The model projects an accumulated discounted cost to the Mexican health 
care system per patient receiving the Colistimethate sodium regimen of $8,525 
compared to $7,384 for non- colistimethate sodium regimen. The base-case analy-
sis presented incremental cost-effectiveness ratios for colistimethate sodium vs 
non- colistimethate sodium grup of $ 2,213 per LYG. These values are in accordance 
with the recommendations of the Commission on Macroeconomics and Health, 
WHO, suggesting that health technologies with ICERs below the per capita GDP are 
considered very cost-effective. Results were robust to various assumptions tested 
in the sensitivity analysis. cOnclusiOns: This study suggest that in the Mexican 
setting, use of non- colistimethate sodium for treatment of infections caused by 
MDR is likely to be cost effective.
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Objectives: To evaluate the cost-effectiveness of micafungin compared to caspo-
fungin in the treatment of invasive Candida infection in China. MethOds: A deci-
sion-tree model was developed to estimate the cost-effectiveness of micafungin and 
caspofungin from the perspective of the whole society. In the model, outcome on 
effectiveness was derived from an international, randomized, double-blind, phase III 
clinic trial and cost data was based on China’s practical situation. In the sensitivity 
analysis we use relative measurement method and absolute measurement method 
to analyze the results. Results: At the end of all antifungal therapy, the treat-
ment success rate of micafungin 100 mg/d group, micafungin 150 mg/d group and 
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Objectives: Comparing the cost-effectiveness of Micafungin and Caspofungin for 
the treatment of systemic candida infections (including invasive candidiasis and 
candidaemia) in Switzerland. MethOds: To this end, a health economic decision 
model, based on a phase-III double-blind RCT with global patient data is used. 
Hospitalization and primary medication costs are based on official Swiss data. The 
effectiveness outcome is defined as successfully treated and alive patients at the 
end of the study period. To test for robustness of cost-effectiveness results, a sub-
group analysis, a two-way sensitivity analysis and a probabilistic sensitivity analysis 
(PSA) are performed. Results: The main analysis shows that 60 % of Micafungin 
patients were successfully treated and survived at the end of study compared to 
58 % of Caspofungin patients. The costs of a Micafungin treatment (CHF 54,503) 
are smaller than the costs of a Caspofungin treatment (CHF 56,704). This results in 
a lower cost-effectiveness ratio for Micafungin (CHF 91,356) than for Caspofungin 
(CHF 98,900). Moreover, Micafungin dominates Caspofungin in the incremental cost-
effectiveness analysis. For European patients only, who can be assumed to be a more 
homogenous group and a better approximation of Swiss patients, the cost-effective-
ness ratio for Micafungin is CHF 88,474 compared to CHF 105,202 for Caspofungin. 
Two-way sensitivity analyses for both, total sample and European sub-sample, 
render Micafungin more cost-effective than Caspofungin in 20 out of 20 scenarios 
(highest incremental cost-effectiveness for Micafungin amounts to CHF 16,382). 
Probabilistic sensitivity analysis shows similar findings. cOnclusiOns: This 
study analyzes the cost-effectiveness of Micafungin as compared to Caspofungin 
for the treatment of systemic candida infections in Switzerland. Both lower costs 
and higher effectiveness of Micafungin render Micafungin as more cost-effective 
than Caspofungin.
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Objectives: China has experienced several severe outbreaks of influenza over the 
past century: 1918, 1957, 1968, and 2009. Influenza itself can be deadly; however, 
the increase in mortality during an influenza outbreak is also attributable to sec-
ondary bacterial infections, specifically pneumococcal disease. Given the history 
of pandemic outbreaks and the associated morbidity and mortality, we investigate 
the cost-effectiveness of a PCV7 vaccination program in China from the context of 
typical and pandemic influenza seasons. MethOds: A decision-analytic model 
was employed to evaluate the impact of a 7-valent pneumococcal vaccine (PCV7) 
infant vaccination program on the incidence, mortality, and cost associated with 
pneumococcal disease during a typical influenza season and influenza pandemic in 
China. Estimates were performed comparing an 85% level of PCV7 coverage among 
all newborn infants during a single year in China relative to a case where no PCV7 
vaccinations occur for both a typical influenza season and a severe influenza pan-
demic in China. The model incorporates Chinese data where available and includes 
both direct and indirect (herd) effects on the unvaccinated population, assuming 
steady state. Costs were calculated using a payer perspective and included vac-
cination program costs and direct medical expenditures from pneumococcal dis-
ease. Results: The model predicts that PCV7 vaccination in China would prevent 
4,855,878 cases of pneumococcal disease and 66,351 deaths in a single year during a 
normal influenza season. The estimated incremental-cost-effectiveness ratios were 
¥24,383 per life-year saved and ¥25,519 per quality-adjusted-life-year gained. During 
an influenza pandemic, the model estimates that vaccination with PCV7 would 
prevent 8,192,158 cases of pneumococcal disease and 659,216 deaths, and would 
be cost-saving. cOnclusiOns: Vaccination with PCV7 in China is cost-effective 
during typical influenza season. During an influenza pandemic, the benefit of PCV7 
in preventing excess pneumococcal morbidity and mortality renders a PCV7 vac-
cination program cost-saving.
PIN58
ECoNoMICs aNalysIs of DIagNostIC MEtHoDs for ClostrIDIuM 
DIffICIlE INfECtIoN
Ni W.1, Hay J.1, Zangwill K.M.2
1University of Southern California, Los Angeles, CA, USA, 2UCLA Center for Vaccine Research, 
Torrance, CA, USA
Objectives: Several molecular diagnostic assays (MDA) are now commercially 
available for the diagnosis of Clostridium difficile infection (CDI). These assays detect 
genomic material associated with the pathogen’s toxin A, B and/or other genes in 
stool samples. Compared with the traditional CDI laboratory assay diagnostics, MDA 
has a shorter turn-around time and better sensitivity, but requires relatively expen-
sive instrumentation. The impact of routine use of MDA on the economics of CDI 
disease (via shorter hospitalization and less morbidity) is not clear. We evaluated 
whether routine use of MDA reduces the health care costs and improves quality-
adjusted life years (QALYs) for CDI patients. MethOds: We performed a decision 
tree analysis to compare cost effectiveness of MBD with enzyme immunoassay 
(EIA) and cytotoxin assay (CA) respectively, using data from published literature 
and experts’ opinions. Analyses were conducted from the societal perspective. Both 
incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) were 
used as criteria for evaluation. Results: The ICER shows that MDA is dominant 
to the other two alternatives. Using a base willingness-to-pay per QALY threshold 
($150,000), the NMB of MDA vs. EIA and CA are around $4,000 and $1,500, respec-
